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Abstract
Purpose: Poly (L-lactic acid) (PLA) microparticles encapsulating Hepatitis B surface antigen (HBsAg)
with alum and chitosan were investigated for their potential as a vaccine delivery system.
Methods: The microparticles, prepared using a water-in-oil-in-water (w/o/w) double emulsion solvent
evaporation method with polyvinyl alcohol (PVA) or chitosan as the external phase stabilising agent
showed a significant increase in the encapsulation efficiency of the antigen.
Results: PLA-Alum and PLA-chitosan microparticles induced HBsAg serum specific IgG antibody
responses significantly higher than PLA only microparticles and free antigen following subcutaneous
administration. Chitosan not only imparted a positive charge to the surface of the microparticles but
was also able to increase the serum specific IgG antibody responses significantly.
Conclusions: The cytokine assays showed that the serum IgG antibody response induced is different
according to the formulation, indicated by the differential levels of interleukin 4 (IL-4), interleukin
6 (IL-6) and interferon gamma (IFN-). The microparticles eliciting the highest IgG antibody
response did not necessarily elicit the highest levels of the cytokines IL-4, IL-6 and IFN-.
Keywords: Hepatitis B surface antigen, vaccine, microsphere, poly (L-lactic acid), chitosan, alum, cytokine
Introduction
Vaccines formulated using polymeric microspheres provide a promising carrier system
for delivery of antigens and several investigations have been carried out in recent years into
the pharmaceutical potential of such formulations (Langer and Folkman 1976;
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 Mathiowitz et al. 1990; O’Hagan et al. 1993a; Alpar et al. 1994; Coombes et al. 1996;
Kersten et al. 1996; Singh et al. 2006). Theoretically, single shot vaccines should be able to
deliver the vaccine at a pre-programmed rate in a controlled release manner, upon
administration of a single dose, thereby conferring lifelong protective immunity
(Raghuvanshi et al. 2002). Moreover, they should be stable and highly immunogenic.
To achieve these objectives, several potential approaches have been explored and current
research focuses on the use of biodegradable polymers in conjunction with alum to
formulate antigen encapsulated microspheres. Microencapsulated antigens are capable of
eliciting both humoral and cellular immune responses in naı¨ve animals, probably as a result
of targeting of the antigen to antigen presenting cells upon release from the microspheres
(Johansen et al. 2000). By careful optimisation of process variables, antigens can be
encapsulated in polymer microspheres and, by tailoring parameters such as degradability of
the polymer, microsphere size and loading capacities, the microspheres can be formulated to
release antigen over extended periods (Gilding and Reed 1979). Poly-(L-lactic acid) (PLA) is
a biodegradable polymer that possesses the ideal qualities of a polymeric biomaterial, i.e.
biodegradability and biocompatibility, and has proven safety and a non-toxic profile (Gilding
and Reed 1979). Encapsulation studies using PLA for formulating microspheres for vaccine
delivery have included several antigens including HBsAg (Singh et al. 1997) and PLA
microspheres have been found to provide adjuvant activity in inducing immune responses
(Raghuvanshi et al. 2002). Antigens such as tetanus toxoid (TT), Yersinia pestis V antigen
and HBsAg have been encapsulated previously in PLA microspheres (Gilding and Reed
1979; Nellore et al. 1992; Almeida et al. 1993; Raghuvanshi et al. 2002; Eyles et al. 2003)
and these have provided encouraging results. The main problems that have been faced are
antigen degradation during processing, low protein loading in the microspheres and
generation of relatively weak immune responses. The incorporation of adjuvants to enhance
immune responses has been investigated and a number of immunostimulatory adjuvants
evaluated (O’Hagan et al. 1993b; Diwan et al. 2001; Raghuvanshi et al. 2002; Tobio et al.
2002; Bramwell et al. 2003; Moschos et al. 2006). Aluminium hydroxide (alum) has been
widely used as an adjuvant and is in use currently an adjuvant in many human vaccine
formulations (Iyer et al. 2004; Moschos et al. 2006). The mechanism of enhancement of
immune responses by alum is due to the triggering of humoral immunity by selective
stimulation of type 2T-helper (Th2) responses (Cox and Coulter 1997). The effect of
incorporation of alum in TT encapsulated PLA (45 kDa) microspheres was studied by
Raghuvanshi et al. (2002). Results of this study indicated that alum adsorbed TT
microspheres elicited significantly higher anti-TT antibody titres, as compared to plain TT
microspheres. In the case of the HBsAg, there is substantial published data that
demonstrates that there is considerable potential for the development of single dose
HBsAg vaccines using controlled release biodegradable polymeric microspheres and there is
extensive information about the release kinetics of the encapsulation (Nellore et al. 1992;
Singh et al. 1997; Shi et al. 2002). However, very little has been reported on the effect of
co-encapsulation of alum and antigen on the physicochemical properties of the microspheres
and immune responses. In view of this, the overall purpose of this study was to study the
effect of co-encapsulation of alum adsorbed HBsAg on microsphere characteristics such as
size, surface charge, loading level, as well as on immune responses. HBsAg encapsulated
PLA microspheres were prepared by a conventional double emulsion solvent
evaporation technique and characterisation of physiochemical properties of the encapsulated
microspheres were then carried out, followed by comparison of immune responses among
encapsulated alum adsorbed HBsAg, HBsAg in plain PLA microspheres and HBsAg in
chitosan coated microspheres in the mouse model.


































 Materials and methods
Materials
Hepatitis B surface antigen (HBsAg) in phosphate buffer at a concentration of
1.68mgmL1 was provided as a gift by Shantha Biotechnics (India). The antigen was a
recombinant yeast derived HBsAg from portions of a commercial batch (Lot #19 D04). Poly
(L-lactic acid) (LACTEL, 147 kDa,) was from Birmingham polymers Inc (USA). Alum in
the form of aluminium hydroxide gel (3% m/v) was obtained from Superfos Biosector
(Denmark). Chitosan (high viscosity) was from Fluka (Germany). RPMI and foetal bovine
serum were from Gibco (UK). L-glutamine and penicillin/streptomycin were from Sigma
(UK). Horseradish peroxidase conjugated goat anti-mouse isotype specific immunoglobulin
was from Oxford Biotechnology (UK). Polyvinyl alcohol (87–89% hydrolysed, 13–23 kDa)
was from Sigma-Aldrich (UK). QuantiPro Bicinchoninic acid assay kit was from Sigma
(UK). SilverQuest silver staining kit was from Invitrogen (USA). DuoSet sandwich ELISA
kits were from R&D Systems (UK). 2,20 azino-bis (3-ethylbenzthiazoline-6-sulphonic acid)
was from Sigma (UK), dichloromethane was from BDH laboratory suppliers (UK). All
other reagents used were of analytical grade.
Methods
Preparation of microspheres. HBsAg-loaded microspheres were prepared by a w/o/w
emulsification solvent evaporation method, this technique has been used extensively for
microencapsulation of many antigens including HBsAg (Yan et al. 1994; Shi et al. 2002).
The theoretical loading of HBsAg for all formulations was 1% m/m of the polymer. Briefly,
PLA was dissolved in 4mL dichloromethane. HBsAg was mixed with 0.5mL of aqueous
solution containing 10% m/v PVA. In the case of the alum containing formulation, the
antigen was initially adsorbed to aluminium hydroxide gel (3% m/v) and then mixed with
0.5mL of 10% m/v PVA. The primary emulsion was formed by dispersing the two
immiscible solutions using an ultra-turrax (T25 Janke & Kunkel, IKA-Labortechnik,
Germany) for 2min at 24 000 rpm. This emulsion was added dropwise to 30mL of 1.25%
m/v PVA solution in deionized water or 0.75% m/v chitosan solution in 1% acetic acid and
homogenised for 6min at 10 000 rpm with a high shear homogenizer (Silverson L4RT,
Silverson Machines, UK). The resultant w/o/w emulsion was magnetically stirred at room
temperature overnight to evaporate the organic solvent. The microspheres were collected by
centrifugation (Beckman J2-21, USA) for 15min at 20 000 rpm and washed once with
deionised water. The resultant suspension was freeze-dried (Virtis, UK) to obtain a free
flowing powder.
Characterization of microspheres. Particle size analyses were performed on microsphere
formulations using a Malvern Mastersizer 2000 (Malvern Instruments, UK). Three
measurements were performed on each sample. The results were analysed by the
Fraunhofer model, mean volume diameters (MVD) and standard deviations (SD) were
calculated.
For morphology and surface characteristics, prepared microspheres were coated with gold
in a 20 nm thickness using a sputter coater (Emscope SC500, Ashford, UK) under vacuum
in an argon atmosphere. The surface morphology of the microspheres was then studied by
scanning electron microscopy (SEM) (Philips/FEI XL30, Philips Co, The Netherlands).
The zeta potential of microspheres was determined using an electrophoretic
light-scattering technique (ZetaMaster, Malvern Instruments, UK). The microspheres


































 were dispersed (2mgmL
1) in 10mM potassium chloride solution. This dispersion was
then added to the ZetaMaster electrophoresis cell, the electrophoretic mobility was
measured and the data converted to zeta potential values. All analyses were carried out in
triplicate.
Actual drug content and encapsulation efficiency. Actual drug content (AC) and encapsulation
efficiency (EE) of microspheres were determined by using QuantiPro BCA Assay Kit which
can detect 0.5–30 mgmL1 of protein. In brief, 5mg of the microspheres were digested in
2mL of 5% m/v sodium dodecyl sulphate (SDS) in 0.1M sodium hydroxide solution.
The amount of antigen was determined as a percentage according to the manufacturer’s
instructions. AC and EE were calculated using the equations (1) and (2). All analyses were







where Mact is the actual HBsAg content in weighed quantity of microspheres, Mms is the
weighed quantity of powder of microspheres andMthe is the theoretical amount of HBsAg in
microspheres calculated from the quantity added in the process.
Assessing the integrity of the antigen. Before and after freeze-drying, samples were assessed
using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) in order to
determine the effects of processing conditions on the integrity of the encapsulated HBsAg.
Sample preparation was as follows; 5mg of microspheres was accurately weighed and
dispersed in 100 mL phosphate buffer saline (PBS, pH 7.3) in 1mL eppendorf tubes and
then kept overnight at room temperature for agitation on a plate rocker in order to extract
the protein from the microspheres. Prior to loading, the samples were vortexed for 30 s to
obtain a homogenous dispersion, and then heated at 95C for 4min with the 1mL treatment
buffer (950mL Laemmli bufferþ 50 mL -mercaptoethanol). Twenty microlitres of each of
the samples was then loaded onto 10% polyacrylamide gels along with a molecular weight
marker (Bio-Rad precision plus protein standards, Bio-Rad Labs, USA) and a standard
HBsAg sample. Gels were visualised using the SilverQuest silver staining kit and imaged
using a UVP gel scanning camera.
Immunisation schedule for HBsAg-loaded microspheres. In vivo studies were performed in
accordance with the Animal Scentific Procedures Act 1986. Twenty-four female BALB/c
mice were randomly divided into six groups of four. In the first, second and third groups,
antigen-loaded microspheres without alum (F1), with alum (F2) and with chitosan (F3)
which are equivalent to 1mg/50 mL of HBsAg were administered subcutaneously (s.c.),
respectively. Alum-HBsAg and Chitosan-HBsAg solutions (equivalent to 1 mg/50 mL of
HBsAg) were applied to the fourth and fifth groups, respectively, and free antigen solution
(1mg/50 mL) was applied as a comparison to the sixth group. Each mouse received 50ml
volume of HBsAg-loaded particle suspension or antigen solution alone as appropriate.
The animals were boosted on day 21 with microspheres or solutions which were equivalent
to 0.5 mg/50 mL of HBsAg. Tail vein blood samples were taken after 15, 60, 250, 300 and 400
days and antibody responses assessed by ELISA.


































 In vitro restimulation of spleen cells with soluble HbsAg. For the analysis of HBsAg specific
cytokines, spleens were harvested upon termination of the experiment and splenocytes
isolated into working media (RPMI supplemented with 10% foetal bovine serum,
L-glutamine and penicillin/streptomycin). Splenocytes were stimulated with HBsAg
(5mgmL1), concanavalin A as a positive control (Sigma, UK) or working media alone
for 48 h and supernatants were taken for analysis of IL-2, IL-4 and IFN- using DuoSet
sandwich ELISA kits in accordance with the manufacturers instructions.
Enzyme-linked immunosorbent assay (ELISA). Antibody responses in serum of the
immunized animals were monitored using a microplate ELISA. The 96-well ELISA
microtiter plates (Dynatech, UK) were coated with 100 ml per well of a 10mgmL1 HBsAg
in PBS solution (pH 7.3) overnight at 4C. The plates were washed three times with 0.05%
v/v solution of Tween 20 in PBS (PBST) using an automatic plate washer. The serum
samples were serially diluted (1 in 32) in PBS using flat bottom high binding microtitre
plates (Immunolon, UK) and 50 mL of each sample was added to each well of the coated
ELISA plates. These were covered and incubated for 1 h at 37C. The plates were again
washed three times with the PBST solution. 50mL of goat anti-mouse horseradish peroxide
conjugate, diluted 1 in 1000 using PBS was added to each well and the plates covered and
incubated again for 1 h at 37C. The plates were again washed three times in PBST and
50 mL of the substrate (2,20azino-bis) 3-ethylbenzthiazoline-6-sulphonic acid (ABTS), at a
concentration of 600mgmL1 in a citrate buffer plus 7.5 mL hydrogen peroxide per 50mL,
was added to each well and incubated at 37C for 20min for colour development.
The optical densities of the plates were then read at 405 nm using the Dynax MRX
microplate reader (Dynax Technologies, UK). End-point titres were expressed as the last
dilution, which gave an optical density at 405nm above the optical density of negative
control after the 30min incubation.
Results and discussion
Preparation and characterisation of the microspheres
The fundamental requirements for the success of the use of biodegradable polymers for
delivery of vaccine antigens are that the microspheres should efficiently entrap (or adsorb)
the antigen; they should be in a suitable size range and possessing appropriate surface
properties to interact with and be taken up by antigen presenting cells. This depends
upon careful optimisation of process parameters and judicious selection of polymer and
adjuvants.
In this study, the formation of chitosan or alum co-encapsulated microparticles was
achieved by a w/o/w double emulsion solvent evaporation method that involved the
incorporation of either the positively charged polysaccharide or the negatively charged alum
in the microparticle formation medium. PLA was selected for the formulation of
microspheres for this study as there have been several previous studies in which it was
shown that PLA was a suitable polymer for encapsulating a variety of proteins (Coombes
et al. 1996; Lee at al. 1997; Raghuvanshi et al. 2002). Prior to this study a preliminary study
was carried out using Bovine serum albumin as a model antigen, the preparation method
was therefore standardised and process parameters were optimised for this study (data is not
shown). There have been previous attempts at encapsulating the HBsAg in microparticles
and HBsAg encapsulated in PLGA microspheres is known to elicit good immune
responses in several investigations (Lee et al. 1997; Singh et al. 1997; Shi et al. 2002).



































The characteristics of the HBsAg encapsulated microspheres fabricated here are
summarised in Table I.
The size of the microspheres is an important criterion in the induction of an antibody
response, since they are in the size range of 1–2 mm and, therefore, in a range suitable for
phagocytosis and uptake by the antigen presenting cells (Kanke et al. 1986; Yamaguchi and
Anderson 1993; Morris et al. 1994). The surface morphology of the particles depends upon
factors such as the nature of the polymer, concentration of the stabiliser and fabrication
parameters (Rafati et al. 1997). All the microsphere preparations produced in this study are
smooth and spherical, with no aggregation (Figure 1).
Microspheres have a particle size smaller than 2 mm diameter and the mean particle size
of microspheres ranged from 1.33 0.02 to 1.93 0.03 mm for empty microspheres
(BF1–BF4) and from 1.13 0.07 to 1.98 0.16 mm for HBsAg encapsulated microspheres
(F1–F4). Incorporation of the antigen or the inclusion of alum and chitosan didn’t change
significantly the particle size and distribution of microspheres (p>0.05) (Table II).
The surface charge in terms of the Zeta potential of the microspheres is an important
determinant for the in vivo behaviour of microspheres and determines their degree of
interaction with the cell surface and their uptake by phagocytotic cells. Surface charges of the
microspheres (Table II) were negative for all formulations except microsphere formulations
containing chitosan (F3 and BF3). Surface charge values between 19.5 and þ27.5mV for
empty microspheres (BF1–BF4) and between 30.6 and þ21.5mV for antigen-loaded
microspheres (F1–F4) were measured. Incorporation of the antigen or the inclusion of alum
reduced the surface charge of microspheres. Alum adsorbed microspheres displayed a
slightly higher negative charge than HBsAg-loaded microspheres, suggesting that the
adsorption of the antigen on alum has caused a shift in charge towards negative. Using
chitosan as a stabiliser in the external aqueous phase instead of negatively charged PVA
significantly increased the surface charge of microspheres when comparing these
formulations (F3: þ21.5mV; BF3: þ27.5mV) (p<0.01). The zeta potential values
measured, as expected, were positive (due to the amine groups of the chitosan molecule)
for the formulations where chitosan was used as the external phase stabiliser. This indicates
that the outer surface of F3 and BF3 formulations consist largely of chitosan.
Yield, actual antigen content and encapsulation efficiency
The production yield, actual antigen content and encapsulation efficiency of microspheres
are given in Table II.








F1 HbsAg 5 PVA (10%) PVA (2.5%)
F2 HBsAg adsorbed alum 5 PVA (10%) PVA (2.5%)
F3 HBsAg 5 PVA (10%) Chitosan (0.75%)
F4 HBsAg 10 PVA (10%) PVA (2.5%)
BF1 – 5 PVA (10%) PVA (2.5%)
BF2 – 5 PVA (10%) PVA (2.5%)
BF3 – 5 PVA (10%) Chitosan (0.75%)
BF4 – 10 PVA (10%) PVA (2.5%)



































The production yield was between 60.8–79.2% for empty particles and 62.8–68.8% for
antigen-loaded micropheres. Antigen loading didn’t affect the yield of microspheres
significantly (p>0.05). In order for the antigen encapsulated microspheres to function as
controlled release delivery systems for the generation of long lasting immune responses, it is
Figure 1. Scanning electron micrographs of the HBsAg encapsulated PLA microspheres prepared
using w/o/w emulsion solvent evaporation method after freeze drying. F1, F2, F3 and F4 formulations
are HBsAg encapsulated PLA microspheres (oil phase amount is 5mL), alum adsorbed HBsAg
encapsulated PLA microspheres, HBsAg encapsulated chitosan coated PLA microspheres and HBsAg
encapsulated PLA microspheres (oil phase amount is 10mL), respectively.
Table II. Production yield, actual antigen content, encapsulation efficiency, mean volume diameter and zeta













F1 62.8 1.12 1.97 0.11 12.34 1.02 1.36 0.02 23.91.0
F2 67.2 1.34 14.62 0.26 98.24 1.28 1.56 0.18 30.63.1
F3 68.8 2.13 12.55 0.21 86.36 2.14 2.12 0.16 21.52.2
F4 63.2 2.87 7.11 0.22 44.96 2.09 1.13 0.07 24.81.5
BF1 68.4 3.08 – – 1.34 0.03 11.52.0
BF2 73.6 5.13 – – 1.78 0.03 19.50.9
BF3 79.2 3.89 – – 2.44 0.14 27.50.9
BF4 60.8 2.75 – – 1.33 0.02 17.80.6


































 necessary that they should contain suitably high levels of the antigen and, for this to take
place, it is necessary to achieve sufficiently high protein loading efficiencies. The actual
HBsAg content of microspheres, expressed as a percentage of the amount of antigen
entrapped in the microspheres, varied between 1.97–14.62 mgmg1 (Table II). It was found
that the antigen content of microspheres which were prepared with alum (F2)
(14.62 0.26 mgmg1) and chitosan (F3) (12.55 0.21 mgmg1) were significantly higher
than the microspheres containing antigen alone (F1) (1.97 0.11 mgmg1) (p<0.01).
While the encapsulation efficiency of the F1 formulation was 12.34 1.02%, the use of
alum (F2) and chitosan (F3) increased the encapsulation efficiency of formulations to
98.24 1.02% and 86.36 2.14%, respectively. The actual content and encapsulation
efficiency can be enhanced significantly by the use of certain excipients that are known to
enhance antigen loading (Yan et al. 1994). Raghuvanshi et al. (2002) have demonstrated
that single doses of antigen encapsulated PLA particles exhibit markedly enhanced antibody
titres when administered with alum. Alum is used as an adsorbent for antigen in the current
HBsAg vaccine formulation and adsorbing first might inhibit the loss of antigen that takes
place during several stages of the formulation process such as during emulsification as well
as washings, during which a significant portion of the unencapsulated antigen is lost.
Iyer et al. (2004) have shown that HBsAg adsorbs strongly onto aluminium hydroxide
adjuvant by means of ligand exchange between the HBsAg phospholipids and surface
hydroxyls of the adjuvant. The adsorption of HBsAg onto alum adjuvant prior to
microencapsulation, therefore, significantly enhanced the antigen loading efficiency of the
PLA microspheres. In the case of chitosan, this is a positively charged polymer and
protonated amine groups of chitosan are able to form complexes with negatively charged
surface antigens. It is suggested that, as a result of complexation between chitosan and
HBsAg, the encapsulation efficiency of the F3 formulation was significantly increased.
Antigen integrity in the encapsulated microspheres
The structural integrity/stability of the encapsulated HBsAg was analysed by SDS-PAGE.
Antigen was extracted from microsphere formulations before and after freeze-drying and run
on gels with different amounts of HBsAg standard (24 kDa) and, upon visualisation of the
gels, it can be observed that the bands seen for the samples are of the same molecular weight
as the standard HBsAg samples (Figure 2). The structural integrity of the antigen is a
prerequisite for the antigen to generate a suitable immune response, denaturation or
inactivation of the protein during processing causes alteration of the native structure of the
protein, indicated by a shift in band formation towards higher or lower MR structures than
the standard (Igartua et al. 1998). This is not seen for any of the samples and, therefore, the
structural integrity HBsAg in these microspheres does not seem to be affected by processing
and has been retained throughout the encapsulation process and storage.
Evaluation of immune responses
Microencapsulated antigens are capable of eliciting both humoral and cellular immune
responses in naı¨ve animals, probably as a result of targeting of the antigen to antigen
presenting cells upon release from the microspheres (Johansen et al. 2000). Inclusion of
additional adjuvants to improve immune responses from polymeric microspheres has been
reported previously (O’Hagan et al. 1993a; Diwan et al. 2001; Tobio et al. 2002) and
aluminium compounds as adjuvants have been used in combination with liposomes (Alving
et al. 1993) and biodegradable polymers (Diwan et al. 1998). The microencapsulation of
alum-adsorbed antigens has also been looked at briefly in order to improve the immunity



































and stabilise the entrapped antigen (Esparza and Kissel 1992; Diwan et al. 1998; Johansen
et al. 2000). In addition, alum enhances the hydrophobicity of polymeric microspheres,
thereby enhancing uptake by antigen presenting cells and improving the magnitude of the
immune response (Raghuvanshi et al. 2002). The enhanced immune responses might be
generated as a result of a synergistic effect due to the presence of alum and the PLA
microspheres. In a study conducted by Feng et al. (2006) it was shown that a single
subcutaneous injection of HBsAg-loaded microspheres with a dose of 7.5 mg of HBsAg per
mouse gave comparable serum antibody titres to those elicited by three injections (2.5 mg of
HBsAg per dose) of the conventional aluminium adjuvant formulated HBsAg vaccine.
The modification of surface characteristics such as the surface charge and mucoadhesive
properties, in the form of chemical modifications of the polymer or in the form of coatings,
may profoundly affect the efficiency with which the microparticles target the delivery of
bioactive agents to mucosally associated lymphoid tissues and to antigen presenting cells.
Many coatings have been used and examples include; chemicals, polymers, antibodies,
bioadhesives, proteins, peptides, carbohydrates, lectins (Baras et al. 1999; Delgado et al.
1999; Kaiserlian and Etchart 1999). It is well known that chitosan has mucoadhesive
properties and has been used in the past as an adjuvant. Chitosan microparticles have been
reported to have immune stimulating activity such as; (i) increasing accumulation and
activation of macrophages and polymorphonuclear cells, (ii) suppressing tumour growth,
(iii) promoting resistance to infections by micro-organisms, (iv) inducing cytokines,
(v) augmenting antibody responses and (vi) enhancing delayed type hypersensitivity and
cytotoxic T lymphocyte responses (Ishihara et al. 1993; Tokumitsu et al. 1999). Jaganathan
and Vyas (2006) have tested surface modified PLGA microparticles using chitosan chloride
in vivo and found that these positively charged particles produced humoral (both systemic
and mucosal) and cellular immune responses.
In this study, following s.c. delivery of HBsAg encapsulated microspheres (F1, F2 and F3
formulations) and solutions of alum-HBsAg, chitosan-HBsAg and free HBsAg which are
equivalent to 1mg of HBsAg, primary and secondary immune responses were assessed
in terms of serum anti-HBsAg IgG levels. Incorporation of chitosan or alum onto/into
Figure 2. SDS-PAGE analysis of HBsAg following extraction of microspheres taken before and after
freeze-drying. Lanes are as follows: (1) HBsAg 50mgml1; (2) HBsAg 25 mgml1; (3) HBsAg
12.5 mgml1; (4) HBsAg 6.75 mgml1; (5) HBsAg extracted from F1; (6) HBsAg extracted from F2;
(7) HBsAg extracted from F3; (8) HBsAg extracted from F4; (9) molecular weight marker.



































microparticles enhanced the serum antibody response to the subcutaneously administered
HBsAg. HBsAg-specific IgG antibody titres obtained were significantly higher (p<0.05) for
all formulations except F1 than free HBsAg, on the 15th day after immunisation, following
one priming dose (Figure 3). The high primary immune responses of the control groups of
alum-HBsAg solution and chitosan-HBsAg solution as compared to the microsphere
formulations can be attributed to the fact that the microspheres are formulated as controlled
release devices and, therefore, the release of the antigen is in a gradual and controlled
manner and, therefore, the immune responses too would follow this pattern, whilst in the
case of the formulations containing free antigen with alum and chitosan, there would be an
enhanced initial response, which may be less likely to be maintained over a longer time scale.
After 60 and 250 days, F2 and F3 formulations displayed enhanced immune responses
and antibody titres 5–6 times higher than PLA microspheres (F1), alum-HBsAg sol,
chitosan-HBsAg sol and free HBsAg sol (Figure 3). After 300 days, F2 and F3 formulations
gave 8 and 10 times higher antibody titres than other formulations and negative and positive
control groups, respectively (Figure 3). The mode of enhancement of immune response to
alum adsorbed HBsAg loaded PLA microparticles or PLA-chitosan microparticles may be
due to the macrophage activation properties of chitosan or the combination of the depot
nature of alum and activation of immune system by chitosan. Thus, the co-encapsulation of
alum in microspheres (F2) or the coating of microspheres with chitosan (F3) led to a
significant enhancement in the magnitude of the immune response of microspheres, as
compared to PLA-HBsAg microspheres.
In vitro restimulation of spleen cells with soluble HBsAg
For the analysis of HBsAg-specific cytokines, splenocytes were stimulated with 5 mgmL1
HBsAg. Stimulation with HBsAg successfully elicited IL-4, IL-6 and IFN- secretion.
Cytokine production was seen to be dependent on the type of adjuvant which had been
Figure 3. HBsAg-specific serum IgG antibody titres after 15, 60, 250, 300 and 400days following s.c.
delivery of microsphere formulations which were equivalent to 1 mg HBsAg. Mice were boosted with
microspheres which were equivalent to 0.5 mg HBsAg on day 21.



































incorporated into/onto particles. These cytokines play potentially important roles in both
innate and adaptive immune responses. IL-4 and IL-6 are potentially important cytokines in
the Th2 cascade, promoting the proliferation and differentiation of B cells into
antibody-producing plasma cells for the production of antibodies. IL-4 promotes IgG1 and
IgE production and decreases IgG2 and IgG3 production. IL-6 stimulates immunoglobulin
secretion and it can be produced within a few hours of infection by macrophages after
ingestion of bacteria (Fraser et al. 1998; Singh et al. 2006). IFN- is secreted by effector Th1
cells after appropriate peptidergic stimuli in conjunction with MHC class II (Mosmann and
Coffman 1989) and leads via macrophage activation to extensive inflammatory processes that
also enable the killing of intracellular pathogens (Bendelac et al. 1997; Singh et al. 2006).
This study shows that the IL-4 and IL-6 responses are higher than IFN- responses,
indicating a Th2 based response, which can be attributed mainly to the route of
administration. Microsphere (F1, F2 and F3) primed spleen cells induced the highest
elevated IL-4 and IL-6 productions significantly higher than the solutions of
chitosan-HBsAg, alum-HBsAg and free HBsAg primed spleen cells (Figure 4).
Incorporation of alum into HBsAg microspheres (F2) has also significantly increased IL-4
and IL-6 production by spleen cells (p<0.05).
The pattern of IFN- production by cultured splenocytes was markedly different from
those of IL-4 and IL-6, and is shown in Figure 4. The use of chitosan either with
microparticles or with free antigen has shown a significant increase in the IFN- production
by spleen cells when compared with the other formulations.
Conclusion
PLA particles were prepared as microparticulate delivery systems for the delivery of HBsAg
by the w/o/w emulsion solvent evaporation method with an aim of assessing the effect of the
Figure 4. Interleukin 4 (IL-4), Interleukin 6 (IL-6) and Interferon gamma (IFN-) production by
mixed spleens cells during suspension culture with 5 mgml1 concentrations of soluble HBsAg. Cells
were derived from immunized mice. Spleens were removed 400 days after s.c. administration of
HBsAg in microspheres.


































 inclusion of alum as a co-adjuvant and modification of the surface charge of the
microspheres by use of chitosan on physiochemical properties of the microspheres as well
as potentiation of antibody responses. Particles prepared were found to have comparable
uniform size and spherical morphology with high loading efficiencies (where alum and
chitosan was used) and retention of antigen integrity. Antigen integrity was also found to be
retained following analysis after freeze drying, indicating that by careful optimisation of
process parameters and judicious use of polymer and excipients, the structural integrity of
the antigen can be preserved during formulation and storage. Characterisation studies
indicated that the inclusion of alum or chitosan significantly enhanced the encapsulation
efficiency of microspheres. In realisation with the objectives of the study, in vivo
investigations were carried out to assess the effect of alum or chitosan inclusion in the
microspheres upon immune responses. As expected, in analysis of both priming and
boosting doses, the highest serum IgG levels are seen in the case of the PLA-HBsAg
microspheres, HBsAg-Alum-microspheres and HBsAg-Chitosan-microsphere formulations
when compared with the free antigen, free antigen plus alum and free antigen plus chitosan.
Subcutaneous delivery of antigen-loaded microspheres was found to elicit potent primary
immune responses in terms of serum IgG, and alum containing HBsAg microspheres
displayed higher serum anti-HBsAg IgG titres consistently, demonstrating that admixed
alum has a strong impact in enhancing the magnitude of immune responses to PLA
microspheres, possibly due to a synergistic immunostimulatory adjuvant effect between the
PLA microspheres and alum adjuvant. However, the surface modified microspheres with
chitosan have also given slightly higher potency and long lasting immune responses when
compared with the alum co-encapsulated microspheres. In addition it was shown that,
at least to some extent, these different formulations may have the capacity to alter qualitative
aspects of the immune response in terms of antigen specific cytokine responses and,
hence, alter the Th1/Th2 characteristics of the immune response. The mode of
enhancement of immune response to alum adsorbed HBsAg-loaded PLA microparticles
or PLA-chitosan microparticles may be due to the macrophage activation properties of
chitosan or the combination of the depot nature of alum and activation of immune system by
chitosan.
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